Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID-19's hidden presence: could the virus lurk in sperm?

NCT ID NCT04487639

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study looks at whether the virus that causes COVID-19 can be found in the semen of men with cancer who are storing sperm before treatment. Researchers will test both the fluid and the sperm cells for the virus and compare results with nasal swabs and blood tests. The goal is to understand if the virus can be present in sperm, which could affect fertility preservation safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diagnostic tests for SARS-CoV-2 (nasopharyngeal swab, semen analysis, and serology)
What this could lead to
If the virus is found in semen, it could inform safety protocols for fertility preservation and raise awareness about potential sexual transmission.
What could go wrong
This is an observational study, so it won't test treatments. The presence of the virus in semen may not be confirmed, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

129 people

The number who actually took part.

Started

Jul 2020

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Man above 18 years of age, of reproductive age, needing oncofertility preservation through spermatozoa cryopreservation prior to a putative gonadotoxic treatment during the COVID-19 pandemic. * Symptomatic and asymptomatic COVID-19 patients. A patient is considered as symptomatic if he presents one or several of the following clinical signs: fever, cough, cephalalgia, myalgia, diarrhea, anosmia, pharyngodynia. * A sufficient number of remaining spermatozoa straws to perform at least six ART attempts Exclusion Criteria: * Azoospermia * Severe Oligo-Astheno-Teratozoospermia (OAT) or Cryptozoospermia * Semen collection failure * Non-emergency fertility preservation or treatment with low gonadotoxic risk

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer COVID-19 infertility disorder neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cryopreservation Fertility Sperm preservation in oncological patients

Contacts and locations

Locations

  • AP-Hôpitaux de Paris - Hôpital Antoine Béclére - Service de Biologie de la reproduction et AMP DPI CECOS

    Clamart, France, 92140, France

  • AP-Hôpitaux de Paris - Hôpital Cochin - Service d'Histologie-Embryologie-Biologie de la reproduction

    Paris, France, 75014, France

  • AP-Hôpitaux de Paris - Hôpital Jean Verdier - Service de Biologie de la reproduction

    Bondy, France, 93140, France

  • AP-Hôpitaux de Paris - Hôpital Tenon - Service de Biologie de la reproduction - CECOS

    Paris, France, 75000, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France, 63000, France

  • CHU de Clermont-Ferrand - Laboratoire de Virologie

    Clermont-Ferrand, France, 63000, France

  • CHU de Dijon - Laboratoire de Biologie de la Reproduction-CECOS

    Dijon, France, France

  • CHU de Grenoble - Laboratoire d'Aide à la Procréation CECOS

    Grenoble, France, 38000, France

  • CHU de Nancy - Laboratoire de biologie de la reproduction - CECOS

    Nancy, France, 54000, France

  • CHU de Reims - Service de Biologie de la Reproduction - CECOS Champagne-Ardenne de Reims

    Reims, 51000, France

  • CHU de Rouen Normandie - Service Biologie de la Reproduction-CECOS

    Rouen, France, 76000, France

  • CHU de Strasbourg - Service de Biologie de la reproduction

    Strasbourg, France, 67000, France

  • CHU de Toulouse - CECOS Midi-Pyrénées

    Toulouse, France, 31000, France

  • Centre Hospitalier intercommunal (CHI) de Poissy Saint Germain en Laye

    Poissy, France, 78300, France

  • Hospices Civils de Lyon - Service AMP-CECOS

    Lyon, France, 69000, France

  • Hôpital de la Conception - AP-Hôpitaux de Marseille - Service AMP-CECOS

    Marseille, France, 13000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.